Exact Sciences Corporation (NASDAQ:EXAS) saw a downside of -3.72% to close Tuesday at $65.30 after subtracting -$2.52 on the day. The 5-day average trading volume is 2,643,040 shares of the company’s common stock. It has gained $70.23 in the past week and touched a new high 1 time within the past 5 days. An average of 3,187,380 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,698,724.
EXAS’s 1-month performance is 24.67% or $14.85 on its low of $45.88 reached on 01/06/23. The company’s shares have touched a 52-week low of $29.27 and high of $84.31, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, EXAS has achieved 31.89% or $15.79 and has reached a new high 6 times. However, the current price is down -22.55% from the 52-week high price.
EXAS stock investors last saw insider trading activity on Jan 09.Condella Sarah (EVP, Human Resources) most recently sold 1,000 shares at $60.00 per share on Jan 09. This transaction cost the insider $60,000. Chief Commercial Officer, Cunningham Everett, sold 16,872 shares at a price of $31.37 on Oct 12. Then, on Aug 05, Gen. Mgr., Precision Oncology Baranick Brian sold 984 shares at a price of $47.12 per share. This transaction amounted to $46,366.
EXAS stock has a beta of 1.36. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.61 while the price-to-book (PB) in the most recent quarter is 3.72.
Exact Sciences Corporation’s quick ratio for the period ended June 29 was 2.20, with the current ratio over the same period at 2.50. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.72, while the total debt to equity was 0.72.. In terms of profitability, the gross margin trailing 12 months is 72.80%. The firm’s gross profit as reported stood at $1.31 billion against revenue of $1.77 billion.
For the quarterly period ending June 29 this year, Exact Sciences Corporation’s cash and short-term investments amounted to $433.81 million against total debt of $2.46 billion. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -12.22% to -$148.76 million, while revenue of -$166.06 million was -11.63% off the previous quarter. Analysts expected EXAS to announce -$1.07 per share in earnings in its latest quarter, but it posted -$0.94, representing a 12.10% surprise. EBITDA for the quarter stood at more than -$81.39 million. EXAS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 3.2 billion, with total debt at $2.46 billion. Shareholders hold equity totaling $177.68 million.
Let’s look briefly at Exact Sciences Corporation (EXAS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 62.35% to suggest the stock is trending Neutral, with historical volatility in this time period at 65.10%.
The stock’s 5-day moving average is $67.09, reflecting a -4.50% or -$3.08 change from its current price. EXAS is currently trading +22.86% above its 20-day SMA, +83.53% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +62.20% and SMA200 by-4.96%.
Stochastic %K and %D was 87.21% and 88.07% and the average true range (ATR) pointed at 3.54. The RSI (14) points at 65.57%, while the 14-day stochastic is at 79.75% with the period’s ATR at 3.45. The stock’s 9-day MACD Oscillator is pointing at -0.50 and 4.84 on the 14-day charts.
In the most recent analyst report for Exact Sciences Corporation (NASDAQ: EXAS), Raymond James downgraded it to a Mkt perform rating. They previously had an Outperform rating on the stock.